DS
RXRX icon

DRW Securities’s Recursion Pharmaceuticals RXRX Stock Holding History

DRW Securities’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8K Sell
10,015
-18,505
-65% -$61.6K ﹤0.01% 901
2026
Q1 		$87.6K Buy
+28,520
New +$110K ﹤0.01% 1190
2025
Q4 		– Sell
-41,409
Closed -$203K – 1631
2025
Q3 		$203K Buy
41,409
+24,812
+149% +$130K ﹤0.01% 1072
2025
Q2 		$84K Buy
+16,597
New +$81.5K ﹤0.01% 1027

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DRW Securities's RXRX Position: Q2 2026 in Review

DRW Securities reduced its Recursion Pharmaceuticals (RXRX) stake by 65% in Q2 2026, selling an estimated $61.6K and leaving 10,015 shares worth $36.8K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

DRW Securities first reported a position in RXRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $203K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • DRW Securities held 10,015 shares of Recursion Pharmaceuticals worth $36.8K as of Q2 2026.
  • DRW Securities sold 18,505 Recursion Pharmaceuticals shares in Q2 2026, an estimated $61.6K.
  • Recursion Pharmaceuticals made up ﹤0.01% of DRW Securities's portfolio in Q2 2026, its #901 holding.
  • DRW Securities first reported a position in Recursion Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • DRW Securities's Recursion Pharmaceuticals position peaked at $203K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.